 |
|
|
| |
COMBINATION OF PEGYLATED INTERFERON AND LAMIVUDINE IS SUPERIOR TO LAMIVUDINE
MONOTHERAPY IN THE TREATMENT OF CHRONIC HEPATITIS B - A RANDOMIZED TRIAL
|
| |
| |
J.J.Y. Sung*, H.L.Y. Chan, A.Y. Hui, F.K.L. Chan, A.M.L. Chim, M.L. Wong,
N.W.Y. Leung,
*Presenting Author
Department Of Medicine & Therapeutics, Chinese University Of Hong Kong, Hong
Kong
Background: Previous studies combining interferon with lamivudine failed to
prove additional benefit in clearance of HBV infection. We aimed to study the
anti-viral effects of pegylated interferon (Peg-IFN) and lamivudine
combination. Patients and Methods: Treatment-naive chronic hepatitis B
patients who had positive HBeAg, HBV DNA >1, 000, 000 copies/ml and ALT
1.3-5X upper limit of normal were recruited into an open-labeled, randomized
study. Patients received either combination treatment (Combo group) with
Peg-IFN 1.5 mcg/kg for 8 weeks, then Peg-IFN plus lamivudine 100mg daily for
24 weeks followed by lamivudine alone for 28 weeks, or lamivudine monotherapy
100mg daily for 52 weeks (Lam group). End-of-treatment and sustained (24-week
post-treatment) virological response (VR, defined as HBeAg seroconversion and
undetectable HBV DNA) and biochemical response (BR, defined as normalization
of ALT) were analyzed. Results: The interim results of first 40 patients who
finished treatment and follow-up were analyzed. There was no difference in
the gender, age and ALT levels between the two groups. The proportion of
patients achieving end-of-treatment and sustained VR in Combo group was
significantly higher than that of Lam group (75% vs 25%, p=0.0005 and 50% vs
10%, p=0.02 respectively). There was no significant difference in the
end-of-treatment and sustained BR between the Combo and Lam groups (95% vs
70%, p=0.1 and 50% vs 30%, p=0.3 respectively). Four patients receiving
Peg-IFN had premature termination of treatment due to serious adverse events.
Conclusion: Combination of Peg-IFN and lamivudine has superior anti-viral
effect to lamivudine monotherapy in the treatment of chronic hepatitis B
infection.
|
|
| |
|
|
|
|
|
